Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138803 | 0.91 | ADORA2A (0.60) | ADORA3ADORA1ADORA2AADORA2BCYP2C19 | |
| SCHEMBL7752324 | 0.90 | ADORA2A (0.59) | ADORA3ADORA1ADORA2AADORA2BCYP2C19 | |
| SCHEMBL6829360 | 0.88 | ADORA2A (0.57) | ADORA3ADORA1ADORA2AADORA2BCYP2C19 | |
| SCHEMBL7867680 | 0.88 | ADORA2A (0.60) | ADORA3ADORA1ADORA2AADORA2BCYP2C19 | |
| SCHEMBL15413277 | 0.87 | ADORA2A (0.55) | ADORA3ADORA1ADORA2AADORA2BCYP2C19 | |
| SCHEMBL5501190 | 0.85 | ADORA2A (0.56) | ADORA3ADORA1ADORA2AADORA2BCYP2C19 | |
| SCHEMBL3970946 | 0.84 | LMNA (0.62) | ADORA3ADORA1ADORA2AADORA2BCYP2C19 | |
| SCHEMBL1611240 | 0.84 | ADORA2A (0.57) | ADORA3ADORA1ADORA2AADORA2BCYP2C19 | |
| SCHEMBL4813930 | 0.84 | ADORA2A (0.57) | ADORA3ADORA1ADORA2AADORA2BCYP2C19 | |
| SCHEMBL766499 | 0.84 | PNP (0.56) | LMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200363381-A1 | METHODS OF QUANTIFYING METHYLGLYOXAL-INDUCED NUCLEIC ACID ADDUCTS | CITY OF HOPE (US) | 2020-11-19 | — | — | US | claimed |
| WO-2019152728-A1 | METHODS OF QUANTIFYING METHYLGLYOXAL-INDUCED NUCLEIC ACID ADDUCTS | CITY OF HOPE (US) | 2019-08-08 | — | — | WO | claimed |
| US-11835499-B2 | Methods of quantifying methylglyoxal-induced nucleic acid adducts | CITY OF HOPE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11835499-B2 | Methods of quantifying methylglyoxal-induced nucleic acid adducts | CITY OF HOPE (US) | 2023-12-05 | — | — | US | disclosed |
| US-20200363381-A1 | METHODS OF QUANTIFYING METHYLGLYOXAL-INDUCED NUCLEIC ACID ADDUCTS | CITY OF HOPE (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200363381-A1 | METHODS OF QUANTIFYING METHYLGLYOXAL-INDUCED NUCLEIC ACID ADDUCTS | CITY OF HOPE (US) | 2020-11-19 | — | — | US | disclosed |
| WO-2019152728-A1 | METHODS OF QUANTIFYING METHYLGLYOXAL-INDUCED NUCLEIC ACID ADDUCTS | CITY OF HOPE (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152728-A1 | METHODS OF QUANTIFYING METHYLGLYOXAL-INDUCED NUCLEIC ACID ADDUCTS | CITY OF HOPE (US) | 2019-08-08 | — | — | WO | disclosed |
| EP-2402047-B1 | Device for detoxification of blood | RENAPTA B V (NL) | 2015-07-29 | — | — | EP | disclosed |
| US-8834400-B2 | Artificial kidney | RELITECH B.V. (NL) | 2014-09-16 | — | — | US | disclosed |
| US-20120283628-A1 | Artificial Kidney | RELITECH B.V. (NL) | 2012-11-08 | — | — | US | disclosed |
| US-8277407-B2 | Artificial kidney | RELITECH B.V. (NL) | 2012-10-02 | — | — | US | disclosed |
| EP-2402047-A1 | Device for detoxification and use of such a device | RenApta B.V. (NL) | 2012-01-04 | — | — | EP | disclosed |
| US-20100185134-A1 | Artifical Kidney | RELITECH B.V. (NL) | 2010-07-22 | — | — | US | disclosed |